These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15233578)

  • 21. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations.
    Sobue I; Takayanagi T; Nakanishi T; Tsubaki T; Uono M; Kinoshita M; Igata A; Miyazaki M; Yoshida M; Ando K
    J Neurol Sci; 1983 Oct; 61(2):235-48. PubMed ID: 6417282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute and chronic effects of thyrotropin-releasing hormone (TRH) on stabilogram in spinocerebellar degenerations.
    Yoshida M; Nakanishi T; Komatsu Y
    Tohoku J Exp Med; 1986 Mar; 148(3):327-31. PubMed ID: 3085285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of buspirone for the treatment of cerebellar ataxia in an older individual.
    Holroyd-Leduc JM; Liu BA; Maki BE; Zecevic A; Herrmann N; Black SE
    Can J Clin Pharmacol; 2005; 12(3):e218-21. PubMed ID: 16278493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spinocerebellar degenerations--clinical aspects and new treatment of ataxia.
    Sobue I
    Jpn J Med; 1985 Feb; 24(1):62-7. PubMed ID: 3923240
    [No Abstract]   [Full Text] [Related]  

  • 26. Augmenting transcranial direct current stimulation with (D)-cycloserine for depression: a pilot study.
    Chan HN; Alonzo A; Martin DM; Mitchell PB; Sachdev P; Loo CK
    J ECT; 2013 Sep; 29(3):196-200. PubMed ID: 23792778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choline chloride in the treatment of ataxia.
    Livingstone IR; Mastaglia FL
    Br Med J; 1979 Oct; 2(6195):939. PubMed ID: 391326
    [No Abstract]   [Full Text] [Related]  

  • 28. [Spinocerebellar degenerations].
    Sobue I
    Nihon Naika Gakkai Zasshi; 1984 Oct; 73(10):1415-31. PubMed ID: 6440937
    [No Abstract]   [Full Text] [Related]  

  • 29. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study.
    Trouillas P; Serratrice G; Laplane D; Rascol A; Augustin P; Barroche G; Clanet M; Degos CF; Desnuelle C; Dumas R
    Arch Neurol; 1995 May; 52(5):456-60. PubMed ID: 7733839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.
    Wilhelm S; Buhlmann U; Tolin DF; Meunier SA; Pearlson GD; Reese HE; Cannistraro P; Jenike MA; Rauch SL
    Am J Psychiatry; 2008 Mar; 165(3):335-41; quiz 409. PubMed ID: 18245177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The stereo-specific effect of D-serine ethylester and the D-cycloserine in ataxic mutant mice.
    Saigoh K; Matsui K; Takahashi K; Nishikawa T; Wada K
    Brain Res; 1998 Oct; 808(1):42-7. PubMed ID: 9795125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects].
    Filla A; De Michele G; Di Martino L; Mengano A; Iorio L; Maggio MA; Campanella G
    Riv Neurol; 1989; 59(2):83-8. PubMed ID: 2505370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin.
    Sakai T; Matsuishi T; Yamada S; Komori H; Iwashita H
    J Neural Transm Gen Sect; 1995; 102(2):159-72. PubMed ID: 8748680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
    Hofmann SG; Meuret AE; Smits JA; Simon NM; Pollack MH; Eisenmenger K; Shiekh M; Otto MW
    Arch Gen Psychiatry; 2006 Mar; 63(3):298-304. PubMed ID: 16520435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis.
    Monaca-Charley C; Stojkovic T; Duhamel A; De Seze J; Ferriby D; Vermersch P
    J Neurol; 2003 Oct; 250(10):1190-4. PubMed ID: 14586600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug treatment.
    Perlman S; Boltshauser E
    Handb Clin Neurol; 2018; 155():371-377. PubMed ID: 29891072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of buspirone for treatment of cerebellar ataxia. An open-label study.
    Lou JS; Goldfarb L; McShane L; Gatev P; Hallett M
    Arch Neurol; 1995 Oct; 52(10):982-8. PubMed ID: 7575226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects.
    van Berckel BN; Lipsch C; Timp S; Gispen-de Wied C; Wynne H; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1997 May; 16(5):317-24. PubMed ID: 9109102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease.
    Takei A; Honma S; Kawashima A; Yabe I; Fukazawa T; Hamada K; Hamada T; Tashiro K
    Psychiatry Clin Neurosci; 2002 Apr; 56(2):181-5. PubMed ID: 11952922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.